Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. Review uri icon

Overview

MeSH Major

  • Anticarcinogenic Agents
  • Breast Neoplasms
  • Practice Guidelines as Topic
  • Tamoxifen

abstract

  • In women at increased risk of BC age ≥ 35 years, tamoxifen (20 mg per day for 5 years) should be discussed as an option to reduce the risk of estrogen receptor (ER) -positive BC. In postmenopausal women, raloxifene (60 mg per day for 5 years) and exemestane (25 mg per day for 5 years) should also be discussed as options for BC risk reduction. Those at increased BC risk are defined as individuals with a 5-year projected absolute risk of BC ≥ 1.66% (based on the National Cancer Institute BC Risk Assessment Tool or an equivalent measure) or women diagnosed with lobular carcinoma in situ. Use of other selective ER modulators or other aromatase inhibitors to lower BC risk is not recommended outside of a clinical trial. Health care providers are encouraged to discuss the option of chemoprevention among women at increased BC risk. The discussion should include the specific risks and benefits associated with each chemopreventive agent.

publication date

  • August 10, 2013

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 23835710

Additional Document Info

start page

  • 2942

end page

  • 62

volume

  • 31

number

  • 23